Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 26 04:00PM ET
40.21
Dollar change
+0.35
Percentage change
0.87
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y12.46% Shs Outstand Perf Week3.98%
SponsorPrincipal Financial Services ETF Type Tagsequity Return% 3Y-11.05% Total Holdings266 Perf Month10.67%
Fund Family Bond Type Tagshealthcare Return% 5Y3.60% AUM16.38M Perf Quarter19.66%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y11.71%
Index Weighting Commodity Type Tagsbiotechnology Return% SI NAV/sh Perf Year13.22%
Active/Passive Quant Type Tagsinnovation Flows% 1M-8.13% 52W Range25.66 - 41.10 Perf YTD10.67%
Dividend TTM- ESG Type Tags- Flows% 3M-59.49% 52W High-2.18% Beta0.97
Dividend Ex-DateDec 29, 2021 Dividend Type Sector/Theme Flows% YTD-67.61% 52W Low56.69% ATR (14)0.65
Expense0.42% Structure Type Region Flows% 1Y RSI (14)63.00 Volatility0.75% 1.01%
Option/ShortNo / No Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.09 Prev Close39.86
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume11.84K Price40.21
SMA205.09% SMA508.26% SMA20015.45% Trades Volume1,042 Change0.87%
Jan-26-22 09:38AM
May-12-21 04:45PM
12:00PM
Aug-20-20 05:25PM
Jul-16-20 04:51PM
01:41PM Loading…
Dec-18-19 01:41PM
Dec-02-19 02:40PM
Oct-23-19 10:10AM
Sep-03-19 05:46PM
Jun-24-19 04:23PM
Apr-11-19 03:33PM
Apr-05-19 08:00AM
Apr-02-19 10:00AM
Mar-12-19 11:05AM
Mar-04-19 11:05AM
01:00PM Loading…
Feb-28-19 01:00PM
Feb-27-19 03:00PM
Feb-14-19 10:05AM
Jan-24-19 01:00PM
Mar-01-17 08:59AM
Aug-31-16 09:00AM
Aug-25-16 10:55AM
Aug-23-16 04:04PM
Aug-22-16 04:15PM
12:05PM
Principal Healthcare Innovators ETF seeks long-term growth of capital. Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies in the healthcare sector. It invests significantly in early-stage companies within the healthcare equipment and supplies, pharmaceuticals, biotechnology, and life sciences industries that are not yet consistently profitable.